Mutations in RAD51D are associated with an increased risk of ovarian cancer [23] and a Finnish founder mutation c.576+1G>A in the gene was significantly more frequent among breast cancer patients with a family history of breast and ovarian cancer (2.9%) than among population controls (0.1%) [24]. This evidence concerns the gene RAD51D and ovarian cancer.